首页> 外文期刊>Hematology. >Identification of new markers discriminating between myeloid and lymphoid acute leukemia.
【24h】

Identification of new markers discriminating between myeloid and lymphoid acute leukemia.

机译:鉴别区分髓样和淋巴样急性白血病的新标志物。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: The heterogeneity of acute myeloid leukemia (AML) with respect to biology and clinical course resides in the fact that patients belonging to the same group show marked differences in their response to chemotherapy, necessitating a refinement of AML classification. METHODS: In order to define molecular markers for AML, we performed microarray analysis on peripheral blood cells from two M5 AML patients, and selected four differentially expressed genes to validate their expression by real-time quantitative PCR (RT-PCR). RESULTS: We have shown that two downregulated genes in AML, those encoding guanine nucleotide-binding protein gamma11 (GNG11) and amphiregulin (AREG), are also downregulated in B-lineage acute lymphoblastic leukemia (B-ALL) and T-lineage acute lymphoblastic leukemia (T-ALL) patients. A second gene, that encoding ceruloplasmin (CP), is upregulated in AML but not in B-ALL and T-ALL. The level of expression of these genes varies from one patient to another. CONCLUSION: Since the number of patients studied is limited, further studies are needed with a larger series of patients to evaluate the potential utility of GNG11, AREG and CP as molecular markers for AML subtype classification. Our study is the first to analyze these genes in AML, B-ALL, T-ALL and chronic leukemia (myeloid and lymphoid) patients by RT-PCR. This rapid and sensitive method could be used to screen these genes in different types of leukemia.
机译:背景:急性髓性白血病(AML)在生物学和临床过程方面的异质性在于,属于同一组的患者对化疗的反应显示出明显差异,因此有必要对AML分类进行完善。方法:为了定义AML的分子标记,我们对两名M5 AML患者的外周血细胞进行了微阵列分析,并选择了四个差异表达基因以通过实时定量PCR(RT-PCR)验证其表达。结果:我们显示,AML的两个下调基因,分别是编码鸟嘌呤核苷酸结合蛋白γ11(GNG11)和双调蛋白(AREG)的基因,在B系急性淋巴细胞白血病(B-ALL)和T系急性淋巴细胞白血病中也下调。白血病(T-ALL)患者。编码铜蓝蛋白(CP)的第二个基因在AML中被上调,但在B-ALL和T-ALL中却不被上调。这些基因的表达水平因患者而异。结论:由于研究的患者人数有限,需要对更多的患者进行进一步研究,以评估GNG11,AREG和CP作为AML亚型分类的分子标记物的潜在效用。我们的研究首次通过RT-PCR分析AML,B-ALL,T-ALL和慢性白血病(髓样和淋巴样)患者中的这些基因。这种快速灵敏的方法可用于筛选不同类型白血病中的这些基因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号